Andrew Stephenson, M.D.
| Appointed: |
2006 |
| Gender: |
Male |
| Languages: |
English
French |
Urology
Taussig Cancer Institute
Biographical Sketch
Andrew Stephenson, MD, is Head of Urologic Oncology at Cleveland Clinic's Glickman Urological and Kidney Institute and a staff member of the Taussig Cancer Institute. His clinical and research focus is the treatment of patients with cancers of prostate, bladder and testis. He has published over 50 articles in peer-reviewed journals since 2002 on issues related to prostate, bladder and testicular cancer, many of which have received international mainstream media attention. He has been invited to speak at several major international oncology conferences on these subjects.
Dr. Stephenson is board-certified in urology by the American Board of Urology and the Royal College of Physicians and Surgeons of Canada. He has received several awards from organizations such as the Prostate Cancer Foundation, American Society of Clinical Oncology, and Society of Urologic Oncology. He is listed as one of the Best Doctors in America. This year, he received the Urology Teacher of the Year award from Cleveland Clinic.
Dr. Stephenson receives grant support for prostate cancer research from the Robert Wood Johnson Foundation. His research focus is on the development of prognostic statistical models called nomograms. These prognostic models provide accurate predictions of treatment outcome for prostate cancer and are widely used for patient counseling. He is on the editorial board for several urology journals, including Urology, and is an ad hoc reviewer for Journal of the National Cancer Institute, Journal of Clinical Oncology, and Journal of Urology.
For patients with prostate cancer, Dr. Stephenson performs both nerve-sparing robotic and open radical prostatectomy. The decision to perform either robotic or open prostatectomy is tailored to the specifics of each patient's cancer and preferences. For patients with bladder cancer, Dr. Stephenson also performs nerve-sparing radical cystectomy, extended pelvic lymphadenectomy, and orthotopic urinary diversion (neobladder or Studer) for both men and women. For select patients with testicular cancer, Dr. Stephenson performs nerve-sparing retroperitoneal lymph node dissection.
Dr. Stephenson's family roots are in Northeast Ohio. He is married with four children.
Education & Fellowships
| Medical School: | University of Western Ontario, London, Ontario, Canada |
|
| Residency: | McGill University, Urology, Montreal, Quebec, Canada |
| Fellowship: | Memorial Sloan-Kettering Cancer Center, Urology, New York, NY |
| Other Education: | (Undergraduate) Colgate University, Hamilton, NY |
Certifications
Urology
Royal College of Physicians & Surgeons of Canada
Specialty Interests
Bladder Cancer, Kidney Cancer, Prostate Cancer, Robotic Prostatectomy, testis cancer, Urinary Diversion.
Innovations & Patents
- Development of several nomograms for prostate cancer. These prognostic models provide accurate predictions of treatment outcome for prostate cancer and are widely used for the counseling of patients with localized and advanced prostate cancer.
Awards & Honors
- 2009 - Best Docs, Cleveland Magazine (2007-2009)
- 2008 - Urology Teacher of the Year, Cleveland Clinic
- 2007 - Selected: Best Doctors in America, 2007-2008
- 2006 - Merit Award, American Society of Clinical Oncology
- 2005 - Prostate Cancer Foundation Award, Society of Urologic Oncology
- 2003 - Scholar-In-Training Award, American Association for Cancer Research
- 2003 - Frank McGill Travel Fellowship, McGill University Health Centre Foundation
- 2002 - Post-Resident Research Scholar, American Foundation for Urologic Disease
- 1993 - Phi Beta Kappa, Eta of New York Chapter, Colgate University
Professional Memberships
- Society of Urologic Oncology
- American Urological Association
- American Society of Clinical Oncology
- American College of Surgeons
- Canadian Urological Association
- American Board of Urology
Specializes in Diseases and Conditions
Specializes in Services
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 5/29/2009 the review process regarding Dr. Stephenson’s disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
